VTYX News and Press, Ventyx Biosciences Inc. From 06/29/22

VTX2735, a candidate from Ventyx Biosciences ( NASDAQ: VTYX ) for autoimmune and autoinflammatory conditions, met safety, tolerability, and pharmacokinetics goals in a phase 1 trial. The trial evaluated single ascending dose and multiple ascending doses. Drug-related ...

Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2 trial planned in CAPS patients to efficiently establish clinical proof of concept Clinical update in Q3 fr...

ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, tod...

Dan Loeb's 13F portfolio value decreased from $14.33B to $7.68B this quarter. The number of positions decreased from 92 to 75. Third Point added CSX & Alcoa while dropping Accenture and Upstart Holdings. They also increased EQT Corporation and Zendesk while reducing Amazon.com and...

Ventyx Biosciences, Inc. (VTYX) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Marty Auster – Chief Financial Officer Raju Mohan – Founder and Chief Executive Officer Bill Sandborn – President and Chief Medical Officers Conference Call Parti...

Ventyx Biosciences press release (NASDAQ:VTYX): Q1 GAAP EPS of -$0.45 beats by $0.07. Cash and cash equivalents of $273.14M For further details see: Ventyx Biosciences GAAP EPS of -$0.45 beats by $0.07

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our selective NLRP3 inhibitor, VTX2735, expected in Q2 2022 Announced the appointment of William Sandborn, MD, as President and Chief Medical Officer, stren...

Credit Suisse has initiated Ventyx Biosciences (NASDAQ:VTYX) with an outperform rating citing the company's Tyrosine kinase 2 (TYK2) inhibitor VTX958 as positioned to become the best in class. The firm has a $53 price target on shares (~224% return based on Friday's close). Analyst Taigo Faut...

ENCINITAS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, toda...

ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, toda...